{'fraction_non_alphanumeric': 0.01592115238817286, 'fraction_numerical': 0.0, 'mean_word_length': 5.502463054187192, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A new era of psoriasis research

Psoriasis is one of the multigenic and multifactorial diseases with an etiology that has yet to be thoroughly determined. Recent interventions with biologics and small-molecule inhibitors in the treatment of psoriasis have caused a drastic paradigm shift. Thanks to these novel therapeutic strategies, psoriasis research has progressed in turn. However, there is still a number of puzzles to be solved. Despite accumulating knowledge of psoriasis genetics through the contribution of the genome project, it still remains controversial whether genome-wide association study (GWAS) is the best tool to identify the responsible gene. Because a number of recent studies have elucidated that psoriasis develops through altered innate and adaptive immunity, it is tempting to assume that psoriasis represents a cutaneous condition as a result of evolutional selection pressure over time so as to be resistant to microbial pathogens. Psoriasis is often comorbid and associated with obesity, diabetes and increased cardiovascular risk, namely metabolic syndrome. What are the molecular implications of these two conditions? Which is the cause and which the effect? In this issue, we have four invited articles on psoriasis research regarding the genetics, immunological pathomechanism and their